PubMed Health⌕ Search

PubMed · 15374133

Delayed decrease of excitatory amino acid neurotransmitters in parietotemporal cortex and hippocampus after complete cerebral ischemia in aged rats.

Abstract

A 15-min period of complete cerebral ischemia (CCI) was used in aged rats to investigate changes in tissue contents of the amino acid neurotransmitters (AANT) glutamate (glu), aspartate (asp), gamma aminobutyric acid (gaba) and glycine (gly) in parietotemporal cortex and hippocampus during ischemia and up to 96 h of postischemic recirculation. The AANT were determined by HPLC. The excitatory AANT glu and asp showed a first decrease at the end of CCI in hippocampus and after 1 h of postischemic recirculation in parietotemporal cortex, reflecting a release of these AANT into the extracellular space with a further loss into the blood. A second decrease in glu and asp was seen after 24 h of postischemic recirculation in hippocampus and after 48 h in parietotemporal cortex. This coincides with previously described disturbances in energy metabolism from 24 h to 96 h in hippocampus and from 48 h to 72 h in parietotemporal cortex in the same experimental model in aged rats. This might be a causal factor in delayed postischemic neuronal damage. A comparison with investigations in young animals reveals an enhanced decrease of glutamate and aspartate tissue contents during the postischemic recirculation period in old rats indicating an enhanced release of these amino acid neurotransmitters. A significant decrease of gaba tissue content seen in hippocampus at 48 h and 72 h of postischemic recirculation with subsequent disproportion of inhibitory AANT (lower) to excitatory AANT (higher) might reflect a greater vulnerability of hippocampus than of parietotemporal cortex to ischemia. A significant decrease in the NMDA-receptor coactivator gly in parietotemporal cortex at the end of CCI and at 48 h, 72 h, and 96 h of postischemic recirculation, which was not seen in hippocampus, might be another reason for higher vulnerability of hippocampus to ischemia.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Müldner, S Hoyer. Delayed decrease of excitatory amino acid neurotransmitters in parietotemporal cortex and hippocampus after complete cerebral ischemia in aged rats.. https://doi.org/10.1016/s0167-4943(96)00724-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗